Screener
Ligand Pharmaceuticals LGND Elutia (CorMatrix) — Financial Royalty Assets, Allowance
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Agenus Bot/Bal | 40,815 | (408) | 40,407 | 40,815 | (408) | 40,407 |
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
| Others | 5,729 | (212) | 5,517 | 5,769 | (214) | 5,555 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's elutia (cormatrix) — financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported elutia (cormatrix) — financial royalty assets, allowance of $837K in Q2 2026.
- What does elutia (cormatrix) — financial royalty assets, allowance mean?
- This reflects the contra-asset account established to account for potential uncollectibility or expected credit losses related to royalty assets from the Elutia and CorMatrix segments. It represents management's estimate of the portion of royalty receivables that may not be realized. A significant increase in this allowance may indicate deteriorating credit quality or collection risks associated with the underlying licensees.
Ask your AI about Ligand Pharmaceuticals's elutia (cormatrix) — financial royalty assets, allowance.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude